Associated Papers
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.
Giudice E et al.
Nature Communications, 2024
38555285 (PubMed )
Supplement: 41467_2024_47215_MOESM7_ESM.xlsx › Sheet1
Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Temko D et al.
The Journal of Pathology, 2018
29604063 (PubMed )
Supplement: PATH-245-283-s020.xlsx › Figure.2.Drivers.Edited
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation.
Gellert P et al.
Nature Communications, 2016
27827358 (PubMed )
Supplement: ncomms13294-s4.xlsx › Phase_II
Select a paper to view details